John Rim, Samsung Biologics president and CEO

Sam­sung Bi­o­log­ics se­cures $400M+ man­u­fac­tur­ing deal with Pfiz­er

Sam­sung Bi­o­log­ics struck a deal with Pfiz­er to man­u­fac­ture the drug­mak­er’s biosim­i­lars port­fo­lio, in­clud­ing its prod­ucts for im­munol­o­gy, in­flam­ma­tion and on­col­o­gy, the South Ko­re­an com­pa­ny an­nounced.

The work will be done at Sam­sung Bi­o­log­ics’ newest site, called Plant 4. The con­tract is worth $411 mil­lion, ac­cord­ing to a fil­ing by the CD­MO.

“This new mean­ing­ful part­ner­ship comes just as our Plant 4 is ful­ly com­plet­ed ear­ly this month as we had pre­vi­ous­ly com­mit­ted and are on the move for fu­ture ex­pan­sion in­to our sec­ond cam­pus in or­der to pro­vide our clients with even more flex­i­ble and ad­vanced man­u­fac­tur­ing tech­nol­o­gy,” Sam­sung Bi­o­log­ics CEO John Rim said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.